Nucleoside Analogs in Treatment of Chronic Lymphocytic Leukemia

References

• Galton D. A.G., Wiltshaw E., Szur L., Dacie J. V. The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukaemia. Brit. J. Haemal. 1961; 7: 73–98
   PubMed Web of Science ®Google Scholar
• Knospe W. H., Loeb V., Jr., Huguley C. M., Jr. Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia. Cancer 1974; 33: 555–562
   PubMed Web of Science ®Google Scholar
• Han T., Ezdinli E. Z., Shimaoka K., Desai D. V. Chlorambucil vs. combined chlorambucil-corticoste-roid therapy in chronic lymphocytic leukemia. Cancer 1973; 31: 502–508
   PubMed Web of Science ®Google Scholar
• Liepman M., Votaw M. L. The treatment of chronic lymphocytic leukemia with COP chemotherapy. Cancer 1978; 41: 1664–1669
   PubMed Web of Science ®Google Scholar
• Oken M. M., Kaplan M. E. Combination chemotherapy with cyclophosphamide, vincristine, and predni-sone in the treatment of refractory chronic lymphocytic leukemia. Cancer Treat. Rep. 1979; 63: 441–447
   PubMedGoogle Scholar
• Montserrat E., Alcala A., Alonso C., Besalduch J., Moraleda J. M., Garcia-Conde J., Gutierrez M., Gomis F., Garijo J., Guzman M. C., Estape J., Rozman C., Participating members of Pethema, Spanish Society of He-matology. A randomized trial comparing chlorambucil plus prednisone vs. cyclophosphamide, melphalan, and prenisone in the treatment of chronic lymphocytic leukemia stages B and C. Nouv. Rev. Fr. Hematol. 1988; 30: 429–432
   PubMed Web of Science ®Google Scholar
• Keating M. J., Scouros M., Murphy S., Kantarjian H., Hester J., McCredie K. B., Hersh E. M., Freireich E. J. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 1988; 2: 157–164
   PubMed Web of Science ®Google Scholar
• Kempin S., Lee B. J., III, Thaler H. T., Koziner B., Hecht S., Gee T., Arlin Z., Little C., Straus D., Reich L., Phillips E., Al-Mondhiry H., Dowling M., Mayer K., Clarkson B. Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan and prednisone). Blood 1982; 60: 1110–1121
   PubMed Web of Science ®Google Scholar
• Keating M. J., Kantarjian H., Talpaz M., Redman J., Roller C., Barlogie B., Velasquez W., Plunkett W., Freireich E. J., McCredie K. B. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
   PubMed Web of Science ®Google Scholar
• Keating M. J., Kantarjian H., O'Brien S., Koller C., Talpaz M., Schachner J., Childs C. C., Freireich E. J., McCredie K. B. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol. 1991; 9: 44–49
   PubMed Web of Science ®Google Scholar
• Piro L. D., Carrera C. J., Beutler E., Carson D. A. 2-chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069–1073
   PubMed Web of Science ®Google Scholar
• Saven A., Carrera C. J., Carson D. A., Beutler E., Piro L. 2-chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leukemia and Lym-phoma 1991; 5: 133–138
   PubMed Web of Science ®Google Scholar
• Grever M. R., Leiby J. M., Kraut E. H., Wilson H. E., Niedhart J. A., Wall R. L., Balcerzak S. P. Low-dose deoxycoformycin in lymphoid malignancy. J. Clin. Oncol. 1985; 3: 1196–1201
   PubMed Web of Science ®Google Scholar
• Dillman R. O., Mick R., McIntyre O. R. Pen-tostatin in chronic lymphocytic leukemia: a phase II trial of cancer and leukemia group B. J. Clin. Oncol. 1989; 7: 433–438
   PubMed Web of Science ®Google Scholar
• Grever M., Leiby J., Kraut E., Metz E., Neidhart J., Balcerzak S., Malspeis L. A comprehensive phase I and II clinical investigation of fludarabine phosphate. Semin. Oncol. 1990; 17(Suppl 8)39–48
   PubMedGoogle Scholar
• Leiby J. M., Snider K. M., Kraut E. H., et al. Phase II trial of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity. Cancer Res. 1987; 47: 2719–2722
   PubMed Web of Science ®Google Scholar
• Grever M. R., Kopecky K. J., Coltman C. A., Files J. C., Greenberg B. R., Hutton J. J., Talley R., Von Hoff D. D., Balcerak S. P. Fludarabine monophos-phate: a potentially useful agent in chronic lymphocytic leukemia. Nouv. Rev. Fr. Hematol. 1988; 30: 457–459
   PubMedGoogle Scholar
• Cheson B. D., Bennett J. M., Rai K. R., Grever M. R., Kay N. E., Schiffer C. A., Oken M. M., Keating M. J., Goldt D. H., Kempin S. J., Foon K. A. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored Working Group. Am. J. Hematol. 1988; 29: 152–163
   PubMed Web of Science ®Google Scholar
• O'Brien S., Kantarjian H., Koller C., Robertson L., Beran M., Estey E., Lerner S., Keating M. Fludarabine-prednisone: a highly effective regimen in chronic lymphocytic leukemia. American Society of Clinical Oncology 1992; 11: 260, (abstr)
   Google Scholar
• Kemena A., O'Brien S., Kantarjian H., Robertson L., Koller C., Beran M., Estey E., Plunkett W., Lerner S., Keating M. J. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leukemia and Lymphoma 1992, in press
   Google Scholar
• Robertson L. E., Chubb S., Meyn R. E., Story M., Ford R., Hittleman W. N., Plunkett W. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 1992, in press
   Web of Science ®Google Scholar
• Carrera C. J., Terai C., Piro L., Saven A., Beutler E., Carson D. 2CdA chemotherapy triggers programmed cell death in normal and malignant lymphocytes. International Journal of Purine and Pyrimidine Research 1991; 2: 38, (abstr)
   Google Scholar
• Boldt D. H., Van Hoff D. D., Kuhn J. G., Hersh M. Effects on human peripheral lymphocytes of in vivo administration of 9-β-D-arabinofuranosyl-2-fluoraden-ine-5′ monophosphate (NSC 312887), a new purine anti-metabolite. Cancer Res. 1984; 44: 4661–4666
   PubMed Web of Science ®Google Scholar
• Beutler E., Piro L. D., Saven A., Kay A. C., McMillan R., Longmire R., Carrera C. J., Morin P., Carson D. A. 2-chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leukemia and Lymphoma 1991; 5: 1–8
   PubMed Web of Science ®Google Scholar
• Steis R. G., Urba W. J., Kopp W. C., Alvord W. G., Smith J. W., II, Longo D. L. Kinetics of recovery of CD4 + T-cells in peripheral blood of deoxycofor-mycin-treated patients. J. Natl. Cancer Inst. 1991; 83: 1678–1679
   PubMed Web of Science ®Google Scholar
• International Workshop on Chronic Lymphocytic Leukemia. Chronic lymphocytic leukemia: recommendations for diagnosis, staging and response criterial. Ann. Intern. Med. 1989; 110: 236–238
   PubMed Web of Science ®Google Scholar
• Kemena A., Keating M. J., Plunkett W. Bioa-vailability of plasma fludarabine and fludarabine triphos-phate (F-ARA-ATP) in circulating cells. Blood 1990; 76: 288a
   Google Scholar
• Liliemark J., Albertioni F., Hassan M., Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′-doexyadenosine in humans: alternative routes of administration. J. Clin. Oncol. 1992; 10: 1514–1518
   PubMed Web of Science ®Google Scholar